Celularity Resale Offering Signals Capital Need Amid Pipeline Push

TL;DR

**Celularity's S-1 reveals a company teetering on the edge, desperately needing cash from uncertain warrant exercises to fund its ambitious pipeline, making it a high-risk bet.**

AI Summary

Celularity Inc. (CELUW) is offering up to 14,078,938 shares of Class A Common Stock on a resale basis, comprising 2,531 shares, 11,732,657 shares issuable upon warrant exercise, and 2,343,750 shares from a convertible note. The company will not receive proceeds from the stock sale, but could gain approximately $28.2 million if all 11,732,657 warrants are exercised for cash. Celularity, a regenerative and cellular medicines company, focuses on placental-derived products like Biovance 3L for soft tissue repair. Key pipeline milestones include a 510(k) application for Celularity Tendon Wrap in August 2025, with FUSE Bone Void Filler targeted for a 510(k) in H2 2026 and Celularity Placental Matrix in H2 2027. The company also plans to assess opportunities to supply MLASCs cell therapy candidates PDA 001 and PDA 002 in states like Florida, which recently expanded access to stem cell therapies. Celularity has incurred net losses since inception and will require substantial additional financing to develop its therapeutic candidates, facing significant competition and potential delisting from Nasdaq if compliance standards are not met.

Why It Matters

This S-1 filing is crucial for investors as it highlights Celularity's ongoing need for capital, despite the current offering being a resale by existing stockholders. The potential $28.2 million from warrant exercises is a lifeline, but its realization is uncertain, posing a significant liquidity risk. For employees and customers, the company's ability to secure future financing directly impacts the progression of its promising pipeline, including the Celularity Tendon Wrap and FUSE Bone Void Filler, and the commercial viability of its regenerative medicine products. In a highly competitive biotechnology landscape, Celularity's financial stability and successful product development are paramount to its long-term survival and market position.

Risk Assessment

Risk Level: high — The filing explicitly states, "We have incurred net losses in every period since our inception" and "Our historical operating results indicate substantial doubt exists related to our ability to continue as a going concern." Furthermore, the company "will need substantial additional financing" and faces the risk of delisting from Nasdaq, which could negatively impact its stock price and ability to access capital markets.

Analyst Insight

Investors should approach CELUW with extreme caution, recognizing the significant going concern risk and reliance on uncertain warrant exercises for capital. Await clearer signs of substantial financing and clinical trial progress before considering an investment, as the current filing suggests a highly speculative opportunity.

Financial Highlights

debt To Equity

Not Disclosed

revenue

Not Disclosed

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

Not Disclosed

Key Numbers

• 14,078,938 — Shares of Class A Common Stock offered for resale (Total shares being offered by Selling Stockholders)
• 11,732,657 — Shares issuable upon warrant exercise (Largest component of the shares offered for resale, representing potential future cash for Celularity)
• $28.2 million — Gross proceeds from cash exercise of all warrants (Potential cash inflow for Celularity, but not guaranteed)
• $1.125 — Closing price of Class A Common Stock on December 30, 2025 (Market price of CELU shares on Nasdaq)
• 290 — Patents and patent applications (Number of intellectual property assets protecting Celularity's platform and programs)
• 2025 — Year of 510(k) application for Celularity Tendon Wrap (Expected submission date for a key biomaterial product candidate)
• 2026 — Year of 510(k) filing objective for FUSE Bone Void Filler (Target year for another biomaterial product candidate filing)
• 2027 — Year of 510(k) filing objective for Celularity Placental Matrix (Target year for a third biomaterial product candidate filing)

Key Players & Entities

• Celularity Inc. (company) — Registrant and issuer of Class A Common Stock
• Robert J. Hariri, M.D., Ph.D. (person) — Chief Executive Officer and Chairman of Celularity Inc.
• Sheppard, Mullin, Richter & Hampton LLP (company) — Legal counsel for Celularity Inc.
• The Nasdaq Capital Market (regulator) — Listing exchange for Celularity's Class A Common Stock
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1 filing
• Anthrogenesis Corporation (company) — Company founded by Robert J. Hariri and acquired by Celgene
• Celgene Corporation (company) — Acquired Anthrogenesis in 2002
• Florida (regulator) — State with new legislation expanding access to stem cell therapies
• GX Acquisition Corp. (company) — Former name of Celularity Inc. before merger

FAQ

Risk Factors

• Substantial Net Losses and Need for Additional Financing [high — financial]: Celularity has incurred significant net losses since its inception and expects to continue incurring losses. The company will require substantial additional financing to fund its operations and development activities. Failure to secure this financing could jeopardize its ability to continue as a going concern.
• Regulatory Hurdles for Product Approval [high — regulatory]: The development and commercialization of Celularity's regenerative and cellular medicine products are subject to stringent regulatory review by agencies like the FDA. The company faces the risk of delays or failure to obtain necessary approvals for its pipeline candidates, such as the 510(k) applications for Celularity Tendon Wrap (2025), FUSE Bone Void Filler (2026), and Celularity Placental Matrix (2027).
• Intense Competition in Regenerative Medicine [medium — market]: The regenerative and cellular medicine market is highly competitive, with numerous companies developing similar therapies. Celularity faces competition from established players and emerging biotechs, which could impact its market share and pricing power.
• Potential Delisting from Nasdaq [medium — financial]: Celularity is at risk of delisting from the Nasdaq Capital Market if it fails to meet the exchange's continued listing standards. This could significantly impair the liquidity of its securities and its ability to raise capital in the future.
• Reliance on Key Personnel and Third-Party Manufacturers [medium — operational]: The success of Celularity's operations depends on its ability to attract and retain key scientific and management personnel. Furthermore, the company relies on third-party manufacturers for the production of its products, introducing potential supply chain risks.
• Intellectual Property Risks [low — legal]: While Celularity possesses a portfolio of 290 patents and patent applications, it faces the risk of intellectual property disputes, challenges to its patent validity, or the inability to secure broad patent protection for its innovations. This could hinder its competitive advantage.

Industry Context

Celularity operates in the rapidly evolving regenerative and cellular medicine sector, which is characterized by significant scientific innovation and a growing demand for advanced therapies. The industry faces challenges related to long development cycles, high R&D costs, and complex regulatory pathways. Key trends include the increasing focus on placental-derived products and cell-based therapies for a range of medical conditions.

Regulatory Implications

Celularity's product development is heavily reliant on navigating the stringent regulatory landscape, particularly the FDA's approval processes for medical devices and cell therapies. The success of its 510(k) applications for key pipeline products is critical. Furthermore, the company must ensure ongoing compliance with Nasdaq listing requirements to maintain its public trading status.

What Investors Should Do

1. Monitor 510(k) application progress
2. Assess future financing needs and sources
3. Evaluate competitive landscape and market adoption
4. Track Nasdaq compliance status

Key Dates

• 2025-08-01: Target 510(k) application for Celularity Tendon Wrap — Represents a key milestone for one of Celularity's biomaterial product candidates, indicating progress towards potential market entry.
• 2026-07-01: Target 510(k) filing objective for FUSE Bone Void Filler — Another significant target for a biomaterial product candidate, demonstrating continued pipeline development and regulatory pursuit.
• 2027-07-01: Target 510(k) filing objective for Celularity Placental Matrix — Marks a longer-term objective for a third biomaterial product candidate, showcasing the breadth of the company's product development strategy.

Glossary

510(k) application

A premarket submission made to the U.S. Food and Drug Administration (FDA) for devices that are not significantly different from a legally marketed device. It is a pathway to market approval. (Crucial for Celularity's product commercialization strategy, as it's the regulatory pathway for its biomaterial candidates.)

Regenerative Medicine

A branch of medicine focused on repairing, replacing, or regenerating damaged cells, tissues, or organs to restore normal function. (This is Celularity's core business area, highlighting the scientific and therapeutic focus of the company.)

Cellular Medicine

A field that uses cells, often stem cells, to treat diseases or injuries. (Complements regenerative medicine and indicates Celularity's approach to developing therapies using biological cells.)

MLASCs

Mesenchymal-like Adipose Stromal Cells. These are a type of stem cell derived from adipose tissue, known for their regenerative properties. (These are the cell therapy candidates (PDA 001 and PDA 002) that Celularity plans to assess, indicating specific therapeutic targets.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (the exercise price) within a specified timeframe. (A significant portion of the shares offered for resale are issuable upon warrant exercise, representing potential future cash for Celularity if exercised.)

Resale Registration Statement

A filing that allows existing shareholders (selling stockholders) to sell their shares to the public. The company does not receive proceeds from these sales. (The current S-1 filing is primarily a resale registration statement, meaning Celularity itself is not raising capital from this specific offering.)

Year-Over-Year Comparison

This S-1 filing focuses on the resale of existing shares and warrants, indicating that Celularity is not currently raising primary capital. Key financial metrics such as revenue, net income, and margins are not detailed in this specific filing, as it is not a comprehensive financial report. The primary focus is on the potential future cash inflow from warrant exercises and the company's pipeline development milestones, which are presented with target dates for 510(k) applications in 2025, 2026, and 2027.

Key Financial Figures

• $0.0001 — quo;us” or our”), par value $0.0001 per share (the “Class A Common St
• $28.2 million — n gross proceeds to us of approximately $28.2 million. However, we cannot predict when and in
• $1.125 — ported on The Nasdaq Capital Market was $1.125 per share. Investing in our Class A C
• $1.28 — based upon a floor conversion price of $1.28 per share. Use of Proceeds We will
• $13.22 — th a weighted average exercise price of $13.22 (giving effect to certain reset provisi
• $1.32 — o certain reset provisions and based on $1.32 per share, the last reported sale price
• $28.44 — th a weighted average exercise price of $28.44 per share; 143,926 shares of Class A

Filing Documents

• forms-1.htm (S-1) — 506KB
• ex5-1.htm (EX-5.1) — 21KB
• ex23-1.htm (EX-23.1) — 4KB
• ex23-2.htm (EX-23.2) — 5KB
• ex-107.htm (EX-FILING FEES) — 31KB
• forms-1_001.jpg (GRAPHIC) — 5KB
• ex5-1_001.jpg (GRAPHIC) — 13KB
• 0001493152-25-029802.txt ( ) — 716KB
• ex-107_htm.xml (XML) — 6KB

USE OF PROCEEDS

USE OF PROCEEDS 9 DIVIDEND POLICY 9 DETERMINATION OF THE OFFERING PRICE 9 PRIVATE PLACEMENTS OF CONVERTIBLE NOTE AND WARRANTS 10 SELLING STOCKHOLDERS 11 PLAN OF DISTRIBUTION 12 DESCRIPTION OF CAPITAL STOCK 14 LEGAL MATTERS 18 EXPERTS 18 WHERE YOU CAN FIND MORE INFORMATION 18 INCORPORATION OF DOCUMENTS BY REFERENCE 18 i ABOUT THIS PROSPECTUS This prospectus relates to the resale by the Selling Stockholders identified in this prospectus under the caption “Selling Stockholders,” from time to time, of up to an aggregate of 14,078,938 shares of Class A Common Stock consisting of 2,531 shares of Class A Common Stock, 11,732,657 shares of Class A Common Stock issuable upon exercise of Warrants to purchase up to 11,732,657 shares of Class A Common Stock and 2,343,750 shares of Class A Common Stock issuable upon conversion of the Convertible Note. We are not selling any shares of Class A Common Stock under this prospectus, and we will not receive any proceeds from the sale of shares of Class A Common Stock offered hereby by the Selling Stockholders, although we may receive cash from the exercise of the Warrants. You should rely only on the information provided in this prospectus, including any information incorporated by reference. We have not authorized anyone to provide you with any other information and we take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained in this prospectus speaks only as of the date set forth on the cover page and may not reflect subsequent changes in our business, financial condition, results of operations and prospects. We are not, and the Selling Stockholders are not, making offers to sell these securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to wh

View Full Filing

View this S-1 filing on SEC EDGAR